APEIRON Capital Ltd’s Novo Nordisk NVO Stock Holding History

APEIRON Capital Ltd’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-37,484	Closed	-$3.41M	–	10
2023 Q3	$3.41M	Buy	+37,484	New	+$3.3M	2.28%	8

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

APEIRON Capital Ltd's NVO Position: Q4 2023 in Review

APEIRON Capital Ltd sold out of Novo Nordisk (NVO) in Q4 2023, closing a stake of 37,484 shares — an estimated $3.41M sold.

APEIRON Capital Ltd first reported a position in NVO in Q3 2023 and held it in 1 quarter. The position peaked at $3.41M in Q3 2023. 1,511 funds tracked by Wall St. Rank hold NVO as of Q4 2023.

APEIRON Capital Ltd reported no remaining Novo Nordisk position as of Q4 2023 after selling out during the quarter.
APEIRON Capital Ltd sold 37,484 Novo Nordisk shares in Q4 2023, an estimated $3.41M.
APEIRON Capital Ltd first reported a position in Novo Nordisk in Q3 2023 and held it in 1 quarter.
APEIRON Capital Ltd's Novo Nordisk position peaked at $3.41M in Q3 2023.
1,511 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2023.

Based on APEIRON Capital Ltd's 13F filing for Q4 2023, filed 1 Feb 2024.